Androgenetic alopecia, alopecia areata
Conditions
Interventions
Treatment group:Intracellular injection of CEFFE
Sponsors
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: Male patients aged 18-60, female patients aged 18-70; 2. Gender: No restriction on gender; 3. Diagnosis of androgenetic alopecia, with male patients classified as Norwood–Hamilton stages I–IVa and female patients classified as Ludwig stages I–II; 4. Diagnosis of alopecia areata, with a SALT score between 50-100, where the current episode has lasted for 6-8 years without spontaneous improvement (SALT score reduction <= 10) in the past 6 months, or the episode has lasted for more than 8 years but there have been regrowth episodes within that period; 5. Multiple other treatments have been tried with poor or no effect; 6. Signed an informed consent form agreeing to participate in this study and is able to cooperate in completing follow-up activities.
Exclusion criteria
Exclusion criteria: 1. Androgenetic alopecia patients who have used anti-androgen drugs within the past 6 months, or have used minoxidil, zidovudine, tamoxifen, finasteride, dutasteride, and other similar medications within the past 12 months; 2. Alopecia areata patients who have used topical glucocorticoids on the lesion within 1 week before starting treatment, or who have received systemic or local injections of glucocorticoids within 8 weeks, or have used topical or oral JAK inhibitors; 3. Pregnant women or women planning to conceive; 4. Patients with wounds or skin breaks on the scalp; 5. Patients currently participating in other clinical trials; 6. Patients with severe internal diseases (such as diabetes, hepatitis, coronary heart disease, arteriosclerosis, glomerulonephritis, hematological disorders, autoimmune diseases, etc.), a history of malignant tumors, or mental or psychological disorders; 7. Patients who have participated in other clinical trials within 30 days before the screening visit for this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| standard photo rating; | — |
Secondary
| Measure | Time frame |
|---|---|
| hair diameter;hair density;sebum secretion level; | — |
Countries
China
Contacts
Public ContactZheyuan Yu
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Outcome results
None listed